Jung AY, et al. - Using data from 2,223 postmenopausal women with nonmetastatic breast cancer from the population-based Mamma Carcinoma Risk Factor Investigation (MARIE) study, researchers assessed pre- and postdiagnosis use of supplements as well as links between postdiagnosis use of antioxidants and other supplements and prognosis, both overall and in women who received chemotherapy and radiation therapy. Multivariate Cox regression analysis was used. They found that 36% and 45% of the women reported pre- and postdiagnosis supplement use, respectively. Following a median follow-up time of 6.0 years following the 2009 re-interview, 240 deaths (134 from breast cancer) and 200 breast cancer recurrences were documented. After adjusting for relevant confounders, increased risk of total mortality and worsened recurrence-free survival were observed in association with concurrent antioxidant use with chemotherapy or radiation therapy among 1,940 women. Findings revealed no association between overall postdiagnosis supplement use and breast cancer prognosis. The current recommendation to avoid the use of antioxidants during chemotherapy or radiation therapy was supported.